G
George Starkschall
Researcher at University of Texas MD Anderson Cancer Center
Publications - 50
Citations - 4436
George Starkschall is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Dosimetry & Radiation therapy. The author has an hindex of 17, co-authored 50 publications receiving 4295 citations. Previous affiliations of George Starkschall include University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Prostate cancer radiation dose response: results of the m. d. anderson phase iii randomized trial
Alan Pollack,Gunar K. Zagars,George Starkschall,John A. Antolak,J. Jack Lee,Eugene Huang,Andrew C. von Eschenbach,Deborah A. Kuban,Isaac I. Rosen +8 more
TL;DR: An increase of 8 Gy resulted in a highly significant improvement in FFF for patients at intermediate-to-high risk, although the rectal reactions were also increased.
Journal ArticleDOI
American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: Quality assurance for clinical radiotherapy treatment planning
Benedick A. Fraass,Karen P. Doppke,Margie Hunt,Margie Hunt,Gerald J. Kutcher,George Starkschall,Robin L Stern,Jake Van Dyke +7 more
TL;DR: The framework and guidance is provided to allow radiation oncology physicists to design comprehensive and practical treatment planning QA programs for their clinics, and the scope of the QA needs for treatment planning is quite broad, encompassing image-based definition of patient anatomy.
Journal ArticleDOI
Preliminary Results of a Randomized Radiotherapy Dose-Escalation Study Comparing 70 Gy With 78 Gy for Prostate Cancer
Alan Pollack,Gunar K. Zagars,L.G. Smith,J. Jack Lee,Andrew C. von Eschenbach,John A. Antolak,George Starkschall,Isaac I. Rosen +7 more
TL;DR: A modest dose increase of 8 Gy using conformal radiotherapy resulted in a substantial improvement in prostate cancer FFF rates for patients with a pretreatment PSA of more than 10 ng/mL, document that local persistence of prostate cancer in intermediate- to high-risk patients is a major problem when doses of 70 Gy or less are used.
Journal ArticleDOI
Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial
A. Pollack,Gunar K. Zagars,George Starkschall,John A. Antolak,J. Jack Lee,Eugene Huang,A. C. Von Eschenbach,Deborah A. Kuban,Isaac I. Rosen,Mark A. Ritter +9 more
Journal ArticleDOI
Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer.
Eugene H. Huang,Alan Pollack,Larry B. Levy,George Starkschall,Lei Dong,Isaac I. Rosen,Deborah A. Kuban +6 more
TL;DR: Dose-volume histogram analyses clearly indicated a volume effect on the probability of developing late rectal complications, and dose escalation may be safely achieved by adherence to dose- volume histogram constraints during treatment planning and organ localization at the time of treatment to ensure consistent patient setup.